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Abstract: Radiotherapy is routinely used as a neoadjuvant, adjuvant or palliative treatment in
various cancers. There is significant variation in clinical response to radiotherapy with or without
traditional chemotherapy. Patients with a good response to radiotherapy demonstrate better clinical
outcomes universally across different cancers. The PI3K/AKT/mTOR pathway upregulation has been
linked to radiotherapy resistance. We reviewed the current literature exploring the role of inhibiting
targets along this pathway, in enhancing radiotherapy response. We identified several studies using
in vitro cancer cell lines, in vivo tumour xenografts and a few Phase I/II clinical trials. Most of the
current evidence in this area comes from glioblastoma multiforme, non-small cell lung cancer, head
and neck cancer, colorectal cancer, and prostate cancer. The biological basis for radiosensitivity
following pathway inhibition was through inhibited DNA double strand break repair, inhibited
cell proliferation, enhanced apoptosis and autophagy as well as tumour microenvironment changes.
Dual PI3K/mTOR inhibition consistently demonstrated radiosensitisation of all types of cancer cells.
Single pathway component inhibitors and other inhibitor combinations yielded variable outcomes
especially within early clinical trials. There is ample evidence from preclinical studies to suggest that
direct pharmacological inhibition of the PI3K/AKT/mTOR pathway components can radiosensitise
different types of cancer cells. We recommend that future in vitro and in vivo research in this field
should focus on dual PI3K/mTOR inhibitors. Early clinical trials are needed to assess the feasibility
and efficacy of these dual inhibitors in combination with radiotherapy in brain, lung, head and neck,
breast, prostate and rectal cancer patients.
Keywords: radiosensitiser; chemoradiotherapy; PI3K; AKT; mTOR inhibitors; rectal cancer; prostate
cancer; glioblastoma multiforme; head and neck cancer; non-small cell lung cancer
1. Introduction
Radiotherapy is widely used in the treatment of cancer. Radiotherapy in isolation or in combination
with chemotherapy may be administered to cancer patients with curative intent [1,2]. Approximately
40% of all patients cured of their cancer will have received radiotherapy as part of their treatment [3].
Radiotherapy can also be used as a neoadjuvant, adjuvant or palliative treatment. Patient response to
radiotherapy is widely variable [4,5]. Patients with a good response to radiotherapy generally benefit
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from a survival advantage over their poorly responding counterparts [4,6]. Those with a good response
can also be managed conservatively using “watch and wait” strategies, potentially avoiding the need
for further invasive treatment (e.g., surgery) [7,8].
The quest to better understand radiotherapy response and resistance has seen decades of research
focus on the intracellular mechanisms activated in response to radiotherapy. Ionising radiation
administered as radiotherapy leads to DNA double strand break (DSB) within the cellular genome [9].
This DNA damage activates intracellular pathways geared at either repairing damaged DNA or
triggering cell death [10,11]. The two main types of DNA repair processes following DNA DSB include
non-homologous end joining (NHEJ) repair and homology directed recombinant (HDR) repair [12,13].
DNA repair through HDR uses template donor DNA from a sister chromatid resulting in a more
accurate repair. NHEJ repair joins the damaged ends of the DNA strand together. This can lead to the
deletion of DNA segments resulting in changes in the genetic code. Where repair is impossible the cell
will undergo apoptosis followed by autophagy. Radiotherapy also promotes significant changes within
the tumour microenvironment [14]. The immune system also plays an important role in eliminating
damaged or dying cells following radiotherapy through the dispersion of immune system stimulating
tumour antigens [15]. Traditionally, 5-fluorauracil (5-FU) based chemotherapy has been used to
sensitise tumours to radiotherapy. However, the efficacy of these drugs in patients remains poor [16].
This is arguably due to the clonal selection of chemoradioresistant subpopulations of cells within the
treated tumour; harbouring pro-survival and anti-apoptotic mutations [17].
Significant stresses are exerted upon the cell and its microenvironment by radiotherapy. This leads
to the activation of pro-survival pathways such as the phosphatidylinositol-3-kinase (PI3K), protein
kinase B (AKT) and mammalian target of rapamycin (mTOR) pathway [18]. This complex intracellular
pathway contains multiple downstream effectors involved in cell proliferation, growth, survival, cell
migration and membrane trafficking (Figure 1 / Figure S1). It is tightly regulated with several activators
and negative feedback loops. The PI3K/AKT/mTOR pathway is activated by substrates binding to
G-protein coupled receptor (GPCR) or receptor tyrosine kinase (RTK) leading to the activation of
membrane bound class-I PI3K proteins [19,20]. Class-I PI3K may also be activated directly by RAS [21].
Activated class-I PI3K phosphorylates transmembrane protein phosphatidylinositol-4,5-bisphosphate
(PIP2) to phosphatidylinositol-3,4,5-bisphosphate (PIP3) [22]. This process is inhibited by phosphatase
and tensin homolog (PTEN) [23]. PIP3 activates AKT directly by phosphorylation or indirectly via the
recruitment of phosphoinositide-dependent protein kinase (PDK1) [24]. mTORC2 is also capable of
direct AKT activation [25].
Phosphorylated AKT (pAKT) leads to the activation of mTORC1, a principal downstream effector
of cell growth, metabolism and protein synthesis [26]. mTORC1 can also be activated by ERK and
RSK via the inhibition of tuberous sclerosis proteins (TSC) 1 or 2 [27,28]. Figure 1 demonstrates the
complexity of this pathway which has multiple overlapping connections to other intracellular pathways.
Activated AKT directly inhibits apoptosis by inhibiting B-cell lymphoma 2 (BCL-2) associated agonist
of cell death (BAD), yes-associated protein 1 (YAP), several proteins of the forkhead (FOX) family,
BCL-2-associated X protein (BAX), BCL-2 proteins and by activating mouse double minute 2 homolog
(MDM2)—an inhibitor of p53 [24]. There is also inhibition of the caspase cell death cascade via the
downstream activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB) or
X-linked inhibitor of apoptosis protein (XIAP) by pAKT [29]. There is indirect or direct activation of
DNA repair pathway proteins such as DNA-dependent protein kinase (DNA-PK) and proteins of the
Fanconi anaemia pathway (FANCD2) by pAKT [30]. AKT activation also leads to cell proliferation, cell
cycle progression via the activation of cyclin D1 and inhibition of p27 and inhibitor cyclin dependent
kinase [31]. In summary, the cumulative effects of AKT activation promotes cell survival, growth,
proliferation, DNA repair and prevents apoptosis.
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Figure 1. The PI3K/AKT/mTOR pathway activation leads to cell growth, increased protein
synthesis, inhibited apoptosis, cell cycle progression and proliferation. For a more detailed
description of the pathway components see Figure S1 in the supplementary materials section.
Regulatory proteins: Phosphatidylinositol-3-kinase (PI3K)—class IA (α, β, δ) or class IB
(γ), Phosphatidylinositol-4,5-bisphosphate (PIP2), Phosphatidylinositol-3,4,5-bisphosphate (PIP3),
3-phosphoinositide-dependent protein (PDK1), Tuberous sclerosis proteins 1 and 2 (TSC-1/2), RAS
homolog enriched in brain (Rheb), Growth factor receptor bound protein 10 (GRB10), Insulin receptor
substrate 1 (IRS 1), Phosphatase and tensin homolog (PTEN), Protein kinase B (AKT), Receptor
tyrosine kinase (RTK), G-protein coupled receptor (GPRCR), Epidermal growth factor receptor
(EGFR). Proteins involved in cell growth and protein synthesis: Mammalian target of rapamycin
(mTOR), S6 kinase beta-1 (S6K1), Eukaryotic translation initiation factor 4E (eIF4E)-binding
protein 1 (4E-BP1), Programmed cell death protein 4 (PDCD4), Ribosomal protein S6 (rpS6).
Proteins involved in promoting cell survival and inhibiting apoptosis: The IκB kinase alpha (IKKα),
IκB kinase beta (IKKβ), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB),
X-linked inhibitor of apoptosis protein (XIAP), BCL2 associated agonist of cell death (BAD),
Cytochrome C (Cyt-C), Yes-associated protein 1 (YAP), p73, Forkhead box proteins (FOX), B-cell
lymphoma 2 protein (BCL-2), BCL-2-like protein 11 (Bim), BCL-2-associated X protein (BAX), Mouse
double minute 2 homolog (MDM2), DNA-dependent protein kinase (DNA-PK), Ku-80, Ku-70
Ribonucleotide reductase (RNR), Deoxynucleoside triphosphate (dNTP), Survivin, Caspase cascade
proteins. Proteins involved in cell cycle progression and proliferation: Cyclin dependent kinase 1
(Cyclin D1), Glycogen synthase kinase 3 (GSK3), p27, Cyclin dependent kinases (CDKs).
The PI3K/AKT/mTOR pathway is often dysregulated in malignancy [32]. Mutations within the
genes coding for PI3K, PTEN, RAS and epidermal growth factor receptor are frequently detected
in cancer [24]. Tumours harbouring these mutations demonstrate radioresistant properties due
to the aberrant activation of this pathway [33–36]. Multiple groups have also demonstrated that
the PI3K/AKT/mTOR pathway activation in response to radiotherapy as a principal mechanism of
radioresistance [18,37–39]. This pathway has also been linked to resistance to chemotherapy [40].
Therefore, the benefits of targeted inhibition of this pathway’s components in the treatment of various
cancers has been extensively researched [41].
There are numerous pharmacological inhibitors of the PI3K/AKT/mTOR pathway which are
widely commercially available (Figure 2). In vitro research has also shown that the inhibition of RAS
by EGFR inhibitors leads to enhanced radiation response by indirectly inhibiting the PI3K/AKT/mTOR
pathway [42]. Therefore, recent attention has shifted towards direct PI3K/AKT/mTOR pathway
component inhibition to enhance radiotherapy response (Tables 1–4). This literature review identified
several studies utilising PI3K, AKT and/or mTOR inhibitors to enhance the radiosensitivity of different
types of tumour. Most research investigating the radiosensitising properties of pharmacological
inhibitors of the PI3K/AKT/mTOR pathway remains at in vitro or in vivo xenograft stages. A few
drugs have undergone early clinical trials (Table 5). The research was broadly categorised based on
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the type of cancer (adenocarcinoma: Table 1, squamous cell carcinoma (SCC) and non-small cell lung
cancer (NSCLC): Table 2, glioblastoma multiforme (GBM): Table 3, and other tumour types: Table 4),
and further subcategorised by type of inhibitor (e.g., single or dual).
1.1. Sensitising Adenocarcinoma to Radiotherapy
1.1.1. Adenocarcinoma of the Rectum
Neoadjuvant long course chemoradiotherapy (LChRT) followed by surgical resection with total
mesorectal excision (TME) is the gold standard treatment for patients with locally advanced rectal
cancer (LARC) [43]. Neoadjuvant treatment modalities involving radiotherapy have been shown to
significantly reduce the risk of local recurrence and increased rates of clear resection margins (R0
resections) in LARC patients. Complete pathological response (pCR) rates of up to 10–30% and
2–6% have been reported in LARC patients following LChRT or short course radiotherapy (SCRT)
respectively [44,45]. Patients with pCR demonstrate a decreased risk of local, distant recurrence and
improved survival [45,46]. It is also important to note that there is a significant proportion of rectal
cancer patients with a poor response to neoadjuvant therapy [47]. There is an urgent clinical need to
improve response to treatment especially in this cohort, given that resistance to chemoradiotherapy
poses a significant treatment challenge.
Research focusing on the use of PI3K/AKT/mTOR pathway inhibitors to improve radiotherapy
response in rectal cancer is still in its infancy. In 2015, Chen et al. (1) described the radiosensitising role
of dual class-I PI3K and mTORC1/C2 inhibitor (NVP-BEZ235) in vitro using KRAS mutant (HCT 116,
SW 620) and wild type (HT 29) colorectal (CRC) cell lines [18]. The authors demonstrated activation of
the PI3K/AKT/mTOR pathway following radiotherapy in the treated cell lines. There was a gradual
increase in the levels of pAKT and phosphorylated mTOR observed up to three hours following
exposure to 5 Gy radiotherapy. Dual inhibition with NVP-BEZ235 led to an increase in radiosensitivity
of all three CRC lines. The authors observed a reduction in cell proliferation as well as loss of expression
of phosphorylated DNA-PKcs and phosphorylated Ribosomal Protein S6 (rpS6) (protein involved in
cell growth and proliferation). A significant reduction in HCT 116 CRC mouse xenografts tumour
size following NVP-BEZ235 and radiotherapy treatment was also observed (p < 0.001). Chen et al.
(2) also demonstrated the radiosensitising potential of combined radiotherapy and NVP-BEZ-235
treatment, followed by continued treatment with the drug; in vitro using CRC cell lines HCT 116,
HT 29 and SW480, and in vivo using HCT 116 mouse xenografts [48]. This study demonstrated that
prolonged treatment after radiotherapy with a dual PI3K/mTOR inhibitor NVP-BEZ235 led to enhanced
apoptosis, inhibition of mTOR signalling, prolonged inhibition of cellular viability and disruption of
DSB repair pathways.
Prevo et al. and Djuzenova et al. evaluated the role of PI3K/AKT/DNA-PK inhibitor PI-103 on
radiosensitising HCT116, DLD-1 and SW480, SW48 CRC cell lines respectively [23,49]. Djuzenova
et al. demonstrated that PI-103 effectively radiosensitised CRC cell lines in the presence of the Heat
Shock Protein 90 (HSP-90) inhibitor NVP-AUY922, when both drugs were added three hours before
irradiation and continued for 24 h after [49]. A reduction in cell proliferation as well as a rise in level of
γ-H2AX was observed. The latter indicating impaired and prolonged DNA DSB repair. The authors
also found that any earlier treatment with PI-103 up to 24 h before radiotherapy led to a decline of the
radiosensitising effect. The authors concluded that the activation of the MEK/ERK pathway following
prolonged inhibition circumvented the PI3K/AKT/mTOR pathway resulting in radioresistance. Prevo
et al. demonstrated radiosensitisation independent of EGFR overexpression, RAS mutation status and
PI3K overexpression in CRC cell lines treated with PI-103 [23]. Reduced pAKT levels, increased G2-M
phase delay, delayed DNA DSB repair and cell proliferation contributed to radiosensitisation. The role
of isolated mTOR inhibition with everolimus as a radiosensitiser was evaluated by Manegold et al.
using CT-26 murine CRC cell lines and an in vivo xenograft mouse model [50]. The authors found that
the decreased expression of vascular endothelial growth factor (VEGF) following mTOR inhibition,
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and the consequent antiangiogenic effects on the tumour microvasculature, was the underlying
mechanism of radiosensitivity. This is one of the limited number of studies demonstrating the cancer
radiosensitisation following isolated mTOR inhibition.
Two early Phase I/II clinical trials evaluated the role of mTOR inhibitors in conjunction with
SCRT in rectal cancer patients (Table 5). Buijsen et al. treated patients with rapamycin one week
before and during radiotherapy [51]. The study evaluated the changes in tumour perfusion status
and treatment feasibility. This study included thirteen patients in phase I and identified a maximum
tolerated dose (MTD) of 6 mg. In phase II, 31 patients were treated with 6 mg of rapamycin and
radiotherapy. A higher rate of post-operative complications were observed in phase-I. Consequently, in
phase II, surgery was performed after 6 weeks as opposed to 3 days following treatment in phase I. The
authors concluded that the combination of SCRT and rapamycin was feasible and safe when using the
phase II treatment regimen. There was a significant reduction in tumour metabolic activity on positron
emission tomography (PET) scans following treatment (p < 0.05). However, no significant increase in
pCR was observed in this small sample sized study. Gelsomino et al. also treated 12 patients with 5-FU,
radiotherapy and mTOR inhibitor everolimus in another Phase I/II clinical trial [52]. Everolimus was
administered 14 days prior to the start of chemoradiotherapy and continued throughout the four-week
course of 5FU and radiotherapy. The authors identified a MTD of 10 mg. No significant increase in
pCR rates was observed. However, the authors demonstrated that the combination of long course
chemoradiotherapy and everolimus was feasible. Further clinical trials are warranted to evaluate the
role of mTOR inhibitors and dual pathway inhibitors in improving pCR rates in rectal cancer patients.
1.1.2. Adenocarcinoma of the Prostate
Radiotherapy alone or in combination with chemotherapy and surgery is used in the treatment of
localised as well as locally advanced PC respectively [8]. However, PC may recur in approximately 39%
of patients who receive radiotherapy for localised disease after a median of 3 years, with an overall
mortality rate of 23% at 5 years [53]. In patients with locally advanced PC treated with radiotherapy
and docetaxel chemotherapy, 22.7% had a recurrence by 10 years, and the overall 5-year mortality was
41.9% [54]. Recurrence following radiotherapy in local or metastatic PC affects a significant proportion
of patients and can be challenging to treat [55]. This is due to the clonal selection and propagation
of radioresistant PC cells within these recurrent tumours. There is scope for improving response to
radiotherapy in recurrent PC as well as improving response to index radiotherapy treatment in PC
patients with targeted therapy.
Chang et al. evaluated the role of class-I PI3K inhibitor (BKM120), mTORC1 inhibitor (rapamycin),
dual class-I PI3K and mTORC1/C2 inhibitors (NVP-BEZ235, PI-103 [also a DNA-PK] inhibitor)
in enhancing response to radiotherapy using three radioresistant PC cell lines [56]. The results
demonstrated that dual pathway component inhibitors were superior to single component inhibitors
in radiosensitising PC cell lines. There was increased apoptosis, autophagy and DNA DSB following
the use of dual inhibitors. The authors also observed decreased expression of proteins involved in
cell cycle checkpoint inactivation and DNA repair (NHEJ as well as HDR). Potiron et al. and Zhu
et al. also demonstrated that NVP-BEZ235 can radiosensitise the PC-3 cell line [57,58]. Potiron et al.
also tested the drug on DU145 PC cell line and evaluated the effects of the dual pathway inhibitor on
both cell lines under hypoxic and normoxic conditions. In their study, dual inhibition of the pathway
successfully radiosensitised both cell lines independent of oxygen concentration or PTEN mutation
status [57]. All three studies demonstrated G2-Metaphase (G2-M) arrest within the cell cycle when
treated with dual inhibitors.
Diaz et al. studied the effects of isolated AKT inhibitor Palomid 529 on NCI-60 cell line panel
in vitro and in vivo using PC-3 xenograft mice [59]. The cell lines were more sensitive to radiotherapy
following treatment with the AKT inhibitor. There were reduced levels of pAKT, VEGF and matrix
metalloproteinase (MMP)-2, 9. Decreased levels of inhibitor of differentiation/DNA binding protein 1
(Id-1) and BCL-2/BAX protein ratio was also noted. The above proteins are involved in DNA DSB
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repair, cell survival and proliferation. Further mouse model work demonstrated greater tumour
shrinkage (77.4%) after treatment with Palomid 529 and 6 Gy radiotherapy compared to single
treatments—(Palomid 529 only—42.9% tumour shrinkage, radiotherapy only 53% tumour shrinkage).
There was inhibited cell proliferation and increased apoptosis within the tumour xenograft. Dumont
et al. treated mouse xenografts containing PC-3 cells with radioisotope (77Lu) tagged gastrin releasing
peptide receptor (GRPr) antagonist, RM2 and mTORC1 inhibitor rapamycin [60]. Combined treatment
with 177Lu-RM2 and rapamycin yielded the highest xenograft median survival (82 days), compared
to 26 days for untreated mice, and 62 days for radioisotope therapy with GRPr antagonist treatment
only group.
A phase-I clinical trial of 15 patients with locally advanced PC conducted by Azria et al.
demonstrated that combined treatment with mTORC1 inhibitor everolimus, hormonal therapy and
radiotherapy was feasible [61]. The MTD of everolimus was 7.5 mg/day. However, given the frequency
of minor side effects, the authors recommend a treatment dose of 5 mg/day for future studies. In a
separate phase-I clinical trial, Narayan et al. used radiotherapy and everolimus to treat patients with a
biochemical recurrence of PC following surgery [62]. The authors concluded that this combination was
feasible in patients with recurrent PC and that everolimus was well tolerated at doses below 10 mg/day.
1.1.3. Other Adenocarcinoma—Pancreas, breast and from the Gynaecological Tract
Radiotherapy is often used as an adjuvant or palliative treatment in patients with breast,
endometrial, uterine and pancreatic cancer [39,50,63–66]. Manegold et al. and Park et al. demonstrated
radiosensitisation of pancreatic cancer cell lines and pancreatic tumour xenografts following treatment
with a mTOR inhibitor (everolimus) and PI3K inhibitor (HS-173) respectively [50,66]. Holler et al.
treated breast cancer cell line MDA-MB-231 with mTOR inhibitor Rapamycin. Treatment with the
drug alone induced radioresistance in these cells due to the indirect activation of the PI3K/AKT/mTOR
pathway components [39]. However, promoting dual pathway inhibition conditions by successful
knockdown of AKT (AKT KO) using scramble RNA (sh-RNA) or AKT1-shRNA and rapamycin,
radiosensitised MDA-MB-231 cells. There was a significant reduction in cell proliferation and
DNA-DSB repair in the AKT KO cells treated with rapamycin and radiotherapy.
Kuger et al. (1) and Fatehi et al. also tested the dual inhibitor NVP-BEZ235 as a radiosensitiser in
breast cancer cell line MDA-MB-231 [63,64]. Fatehi et al. demonstrated that these triple negative breast
cancer cells were most radiosensitised when pre-treated with interlukin-6, sirtuin 1 (SIRT1) activator
(SRT1720), NVP-BEZ235 [63]. Kuger et al. (1) demonstrated that dual inhibitor NVP-BEZ235 could
radiosensitise MDA-MB-231 cells as well as oestrogen receptor positive breast cancer cell line MCF-7,
independent of oxygenation status [64]. Research has shown that there are significant variations in
the oxygen delivered to the different regions of a solid tumour [67]. Subpopulations of cells within
a tumour exposed to different oxygen levels exhibit variable chemoradiotherapy sensitivity [64,68].
The drug radiosensitised hypoxic, normoxic and re-oxygenated cells to the same extent. There was
induction of autophagy, delayed DNA DSB repair, inhibited PI3K/mTOR signalling after treatment
with the dual inhibitor and radiotherapy, independent of oxygenation status. These findings suggest
that pathway inhibition could potentially radiosensitise the heterogeneous population of cells within
a tumour.
Miyasaka et al. demonstrated that TP53 mutation status and PI3K pathway activation contributed
to radiotherapy resistance [65]. Nevertheless, the authors successfully radiosensitised endometrial
cancer cells containingTP53 andPI3Kmutations using the dual PI3K/mTOR inhibitor NVP-BEZ235. The
drug in combination with radiotherapy successfully inhibited PI3K/AKT/mTOR signalling which led to
reduced cell proliferation and reduced expression of the hypoxia Inducing Factor 1- α (HIF1-α)/VEGF
pathway proteins. HIF1-α silencing with small interfering RNA (siRNA) enhanced radiosensitivity
further by reducing the sub-G1 cell population. The authors demonstrated the significant relationship
between the PI3K/AKT/mTOR pathway and the HIF-α/VEGF pathway in radioresistance, and identified
VEGF, HIF-α as potential targets for radiosensitising therapies.
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Table 1. Preclinical studies exploring the role of PI3K, AKT and/or mTOR inhibitors radiosensitising adenocarcinoma.
Author Year Type ofCancer Experimental Model Drug (s) Tested Drug Category
Radiotherapy
Dose Summary Outcome
Fatehi et al.
[63] 2018 Breast
In vitro (cell line):
MDA-MB231 NVP-BEZ235
PI3K and mTOR
inhibitor
2 Gy (Gamma
radiation)
NVPBEZ235 related radiotherapy sensitivity
significantly increased by IL-6 pre-treatment followed
by exposure to sirtuin 1 inhibitor SRT1720 (p < 0.05)
Holler et al.
[39] 2016 Breast
In vitro (cell line):
MDA-MB-231 Rapamycin mTOR inhibitor
Variable range
(0–5 Gy)
Rapamycin induced radioresistance in MDA-MB-231
breast cancer cells
AKT knockdown by scramble sh-RNA or
AKT1-shRNA leads to statistically significant
Rrapamycin induced radiosensitisation
Kuger et
al.(1) [64] 2014 Breast
In vitro (cell lines):
MCF-7, MDA-MB-231 NVP-BEZ235
PI3K and mTOR
inhibitor
Variable range
(0–8 Gy)
Radiosensitisation observed independent of hypoxia
Depleted levels of pAKT, inhibited HIF-1α expression,
PI3K/mTOR signalling
There was autophagy induction and delayed DNA
repair
Miyasaka
et al. [65] 2015 Endometrial
In vitro (cell lines):
HEC-108, HEC-6,
HEC-151, Ishikawa,
HEC-59,
HEC-50B,HEC-1B,
HEC-116
NVP-BEZ235 PI3K and mTORinhibitor
Variable range
(2–6 Gy)
Suppression of the HIF1-α/VEGF pathway
Targeting the PI3K/mTOR or HIF-1α pathways could
improve radiosensitivity
Chen et al.
(2) [48] 2019 CRC
In vitro (cell lines): HCT
116, HT 29, SW480
In vivo (xenograft):
HCT-116 + mice
NVP-BEZ235
(maintenance
therapy)
PI3K and mTOR
inhibitor
Variable range
(1–5 Gy)
Enhanced apoptosis
Prolonged inhibition of cellular viability
Disruption of DSB repair pathways
Djuzenova
et al. [49] 2016 CRC
In vitro (cell lines):
SW480, SW48
PI-103
(+ NVP-AUY922)
PI3K, mTOR,
DNA-PK inhibitor
HSP-90 inhibitor
Variable range
(0–8 Gy)
Enhanced radiosensitising effect following treatment
when treatment started 3 h before radiotherapy and
continued for 24 h after radiotherapy
Chen et al.
(1) [18] 2015 CRC
In vitro (cell lines): HCT
116, SW 620 (KRAS
mutant), HT 29 (KRAS
wild type)
In vivo (xenograft):
HCT-116 + mice
NVP-BEZ235 PI3K and mTORinhibitor
Variable range
(0–6 Gy)
Dose dependent increase in radiotherapy sensitivity
and increased apoptosis after treatment with drug and
radiotherapy
Loss of expression of proteins responsible for DNA
damage repair, cell growth and proliferation
Significant reduction in xenograft tumour size
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Table 1. Cont.
Author Year Type ofCancer Experimental Model Drug (s) Tested Drug Category
Radiotherapy
Dose Summary Outcome
Prevo et al.
[23] 2008 CRC
In vitro (cell lines):
HCT116, DLD-1 PI-103
PI3K, mTOR and
DNA-PK inhibitor
Variable range
(0–6 Gy)
Reduced AKT phosphorylation
Radiosensitisation independent of PI3K
overexpression, EGFR and RAS mutation status
Manegold
et al. [50] 2008
CRC and
Pancreatic
Cancer
In vitro (cell line): CT-26
(murine CRC) L3.6pl
(human pancreatic)
In vivo (xenograft):
CT-26/L3.6pl + mice
Everolimus mTOR inhibitor 10 Gy or 20 Gy
Radiosensitising effects observed.
Significant reduction in tumour size of pancreatic and
CRC cell xenografted mice treated with drug and
radiotherapy compared to control (p < 0.05)
Park et al.
[66] 2017
Pancreatic
Cancer
In vitro (cell lines):
Miapaca-2, PANC-1
In vivo (xenograft):
Miapaca-2 + mice
HS-173 PI3K inhibitor Variable range(0–10Gy)
G2/M cell cycle arrestM
Inhibited Ataxia-Telangiectasia Mutated (ATM)
protein and DNA-PKcs
Improved radiotherapy response by inhibiting the
DNA damage-repair pathways
Dumont et
al. [60] 2019
Prostate
Cancer
In vivo (xenograft): PC-3
+ mice Rapamycin mTOR inhibitor
Radioisotope
treatment
(Lu-labeled GRPr
antagonist)
Dose—37 MBq (for
72 h)
Rapamycin alone had no effect.
With rapamycin and GRPr antagonist, more
effective radiosensitisation observed in xenografts
Chang et al.
[56] 2014
Prostate
Cancer
In vitro (cell line):
CAP-RR
BKM120
Rapamycin
NVP-BEZ235
PI-103
PI3K Inhibitor
mTOR
inhibitorPI3K and
mTOR inhibitor
PI3K, mTOR and
DNA-PK inhibitor
6 Gy
Dual inhibitors superior at radiosensitising –
increased apoptosis and autophagy
Dual inhibition led to G2/M arrest and suppressed
DSB repair mechanisms
Potiron et
al. [57] 2013
Prostate
Cancer
In vitro (cell lines): PC-3,
DU 145 NVP-BEZ235
PI3K and mTOR
inhibitor
Variable range
(0–12.5 Gy)
Radiosensitised both cell lines independent of oxygen
concentration or PTEN mutation status
G2/M arrest
Zhu et al.
[58] 2013
Prostate
Cancer In vitro (cell line): PC-3 NVP-BEZ235
PI3K and mTOR
inhibitor
Variable range
(0–10 Gy)
Radiosensitising effects on PC3 cell line after treatment
G2/M arrest
Diaz et al.
[59] 2009
Prostate
Cancer
In vitro (cell lines):
NCI-60 prostate cancer
cell line panel
In vivo (xenograft): PC-3
+ mice
Palomid 529 AKT inhibitor Variable range(2–8 Gy)
Decreased expression of proteins involved in cell
survival and proliferation
Xenografts demonstrated greater tumour shrinkage
(77.4%) after treatment
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1.2. Sensitising Squamous Cell Carcinoma and Non-Small Cell Lung Cancer to Radiotherapy
1.2.1. Head and Neck Squamous Cell Carcinoma
Approximately half a million patients are diagnosed annually with head and neck (H&N) cancer
worldwide [69]. Over 90% of H&N cancer is SCC, originating anywhere along the nasal, para-nasal
sinuses, oral cavity or pharyngeal mucosa [70]. Radiotherapy is used in the treatment of H&N SCC in
combination with surgery and chemotherapy in the neoadjuvant or adjuvant setting [71]. Prognosis
following treatment depends on tumour site and stage [72].
We identified several studies evaluating the role of PI3K/AKT/mTOR pathway inhibition
radiosensitising H&N SCC (Table 2). Seven of these studies demonstrated the efficacy of dual
PI3K and mTOR inhibitors in radiosensitising H&N SCC cell lines [23,37,73–77]. Five of these seven
studies (Yu et al., Leiker et al., Liu et al., Cerniglia et al. and Fokas et al. (2) demonstrated radiosensitising
effects of dual inhibition in H&N SCC xenograft mice. NVP-BEZ 235 was the most frequently used
dual inhibitor. Several other dual PI3K, mTOR inhibitors (PF-05212384, GSK2126458, NVP-BGT226
and PKI-587) yielded similar results [73–75,77]. Dual inhibition consistently demonstrated reduced
cell proliferation, reduced pAKT, G2-M phase delay and reduced DNA DSB repair characterised by
the presence of increased levels of γ-H2AX [23,73,74,77].
Yu et al. compared the dual inhibitor NVP-BEZ235 against isolated mTOR inhibitors (everolimus
and AZD2014) in vitro using H&N SCC cell lines and in vivo using a xenograft model [37]. In this
study, dual inhibition was superior to isolated mTOR inhibition, at radiosensitising H&N cell lines.
Furthermore, a statistically significant reduction in xenograft tumour size was observed following
treatment with a dual inhibitor and radiotherapy (p = 0.000017). Impaired AKT/mTOR signalling
and G1 phase arrest contributed to radiosensitivity in vitro and in vivo in the dual inhibitor group.
Bozec et al. also explored the role of isolated mTOR inhibition in radiosensitising H&N SCC CAL33
mouse xenografts [78]. Treatment with mTOR inhibitor and radiotherapy failed to demonstrate a
significant reduction in xenograft tumour size over the control group. However, when combined with
traditional chemotherapy, a VEGFA inhibitor (bevacizumab) and radiotherapy, there was significant
anti-proliferative effects and a reduction in xenograft tumour size. Isolated mTOR inhibition is therefore
unlikely to radiosensitise H&N SCC cells.
Two early clinical trials evaluating pathway inhibitors as radiosensitisers are currently in progress.
A Phase Ib study (ClinicalTrials.gov identifier, NCT02113878) is evaluating the role of BKM120 (PI3K
Inhibitor) in combination with cisplatin and radiotherapy in high risk locally advanced H&N SCC.
Another Phase I trial is evaluating the feasibility of radiotherapy with everolimus and cisplatin for
patients with head and neck cancer (ClinicalTrials.gov identifier, NCT00858663). The results from these
trials are pending.
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Table 2. Preclinical studies exploring the role of PI3K, AKT and/or mTOR inhibitors radiosensitising SCC and NSCLC.
Author Year Type ofCancer Experimental Model Drug (s) Tested Drug Category
Radiotherapy
Dose Summary Outcome
Assad et al.
[79] 2018 Cervical SCC In vitro: (cell line): HeLa
Temsirolimus,
everolimus, resveratrol,
curcumin,
epigallocatechin gallate
mTOR inhibitors 2 Gy Radiosensitisation observed with mTOR inhibitorsthrough late apoptosis and necrosis
Yu et al.
[37] 2017
Head and
Neck (Oral)
SCC
In vitro (cell lines): OML1,
OML1-R, SCC4, SCC25,
Patient derived cell lines
In vivo: (xenograft) OML1-R
+ mice
NVP-BEZ235
Everolimus
AZD2014
BKM120
PI3K and mTOR
inhibitor
mTOR inhibitorm
TOR inhibitor
PI3K inhibitor
10 Gy or 0–4 Gy
(variable)
Dual inhibition of PI3K and mTOR performed
significantly better by inhibiting cell proliferation
BEZ235 + radiotherapy reduced cell viability
2.4–6.3-fold
Radiotherapy with BEZ235 significantly suppressed the
growth of xenograft tumours (p =0.00017)
Leiker et al.
[75] 2015
Head and
Neck SCC
In vitro (cell lines):
UMSCC1-wtP53,
UMSCC46-mtP53, normal
human fibroblast line (1522)
In vivo (xenograft): UMSCC1
+ mice
PF-05212384 PI3K and mTORinhibitor
Variable range (0
to 8 Gy)
Enhanced radiosensitisation demonstrated in vitro and
in vivo after treatment
Compared to normal human fibroblasts tumour cells
more effectively radiosensitised.
Liu et al.
[73] 2015
Head and Neck
(Naso-pharyngeal)
SCC
In vitro (cell lines): CNE-2,
5-8F, 6-10B, CNE-1, NP69
In vivo (xenograft): 5-8F +
mice
GSK2126458
PKI-587
PI3K and mTOR
inhibitor
PI3K and mTOR
inhibitor
4 Gy
Both drugs:
Increased DNA damage and G2–M cell cycle delay
Induced apoptosis and inhibited cell proliferation
Significantly inhibited xenograft tumour growth and
proliferation
Suppressed phosphorylation of mTOR, AKT and
4E-BP1
Cerniglia et
al. [74] 2012
Head and
Neck SCC
In vitro (cell line): SQ20B
In vivo: (xenograft) SQ20B +
mice
NVP-BEZ235 PI3K and mTORinhibitor
Variable range
(0 to 6 Gy)
Knockdown of pathway components AKT, p110- α, or
mTOR led to radiosensitisation, but not to the same
extent as NVPBEZ235
Loss of resolution of H2A histone family member X foci
(γ-H2AX)
Induced autophagy in cell lines and xenograft tumours
Fokas et al.
(1) [77] 2012
Head and
Neck
(laryngeal and
hypo
-pharyngeal)
SCC
In vitro (cell lines): SQ20B,
FaDu
NVP-BGT226
NVP-BEZ235
PI3K and mTOR
inhibitor
PI3K and mTOR
inhibitor
6 Gy
Both inhibitors can enhance radiation-induced killing of
tumour cellsBoth inhibited phosphorylation of AKT,
mTOR and led to DNA damage persistence (increased
γ-H2AX foci)
G2 cell cycle delay
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Table 2. Cont.
Author Year Type ofCancer Experimental Model Drug (s) Tested Drug Category
Radiotherapy
Dose Summary Outcome
Bozec et al.
[78] 2011
Head and
Neck SCC
In vivo (xenograft): CAL33 +
mice
Temsirolimus (+
cetuximab and
bevacizumab)
mTOR inhibitor
Cytotoxic
chemotherapy +
VEGF inhibitor
6 Gy
three times a week
Longest delay in tumour growth observed when
temsirolimus combined with cetuximab, bevacizumab
and radiotherapy (p-0.01)
Reduced Ki-67 and BCL2 implying decreased tumour
proliferation as well as anti-apoptotic effects
Fokas et al.
(2) [76] 2011
Head and
Neck SCC
In vitro (cell line): FaDU
HRE-Luc
In vivo (xenograft): FaDU
HRE-Luc + mice
NVP-BEZ235BKM120
PI3K and mTOR
inhibitor
PI3K inhibitor
6 Gy
Dual inhibitor modulated the tumour
microenvironment
Radiosensitised tumours by prolonging the time taken
for normalisation of tumour vasculature
Prevo et al.
[23] 2008
Head and
Neck SCC In vitro (cell line): SQ20B PI-103
PI3K, mTOR and
DNA-PK inhibitor
Variable range
(0–6 Gy)
Reduced AKT phosphorylation. Persistent DNA
damage after treatment (increased γ-H2AX foci).
G2/M phase delay.
Overall effects led to reduced cell survival.
Holler et al.
[39] 2016 NSCLC
In vitro (cell lines): H661,
H460, SK-MES-1, HTB-182,
A549
Rapamycin
MK-2206
mTOR inhibitor
AKT inhibitor
Variable range
(0–5 Gy)
AKT inhibition led to rapamycin induced
radiosensitisation in radio-resistant NSCLC cells
Dual inhibition of AKT and mTOR significantly
inhibited DNA DSB repair compared to single inhibition
Toulany et
al. [38] 2016 NSCLC
PI-103
PD98059
PI3K, mTOR and
DNA-PK inhibitor
MEK inhibitor
4 Gy
Decreased DNA DSB repair by inhibited DNAP-PKcs
activity short term
Combining MEK inhibitor prevented indirect activation
of AKT (RAS/RAF/MEK pathway). This led to more
prolonged and greater radiosensitisation effects
Kim et al.
(1) [80] 2014 NSCLC
In vitro (cell line): H460-Luc2
(cisplatin resistant clone)
In vivo (xenograft):
H460-Luc2 (cisplatin resistant
clone) + mice
NVP-BEZ 235 PI3K and mTORinhibitor
Variable range
(0–6Gy)
BEZ-235 enhanced radiosensitivity (p-0.01)
Increased autophagy and cell proliferation
Significant tumour growth delay observed in treated
xenografts
Reduced caspase-3 activity, cell proliferation and
vascular density
Kim et al.
(3) [81] 2013 NSCLC
In vitro (cell lines): H1650,
HCC827 Everolimus mTOR inhibitor
Variable range
(0–3Gy)
Enhanced autophagy following mTOR inhibition and
radiotherapy
Radioresistance observed in HCC827 cell lines
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Table 2. Cont.
Author Year Type ofCancer Experimental Model Drug (s) Tested Drug Category
Radiotherapy
Dose Summary Outcome
Mauceri et
al. [82] 2012 NSCLC
In vitro (cell line): A549
In vivo (xenograft): A549 +
mice
Everolimus mTOR inhibitor 5 × 6 Gy
Everolimus altered gene expression in treated cells
Everolimus with radiotherapy significantly slowed
tumour growth compared to radiotherapy alone in
xenograft (p = 0015).
Konstantinidou
et al. [36] 2009 NSCLC
In vitro (cell lines): H23,
H460, H2122
In vitro (mouse cell lines):
LKR10, LKR13
In vivo (xenograft): H460 +
mice
NVP-BEZ235
LY294002 + rapamycin
PI3K and mTOR
inhibitor
PI3K and PI3K-like
kinase inhibitor +
mTOR inhibitor
Variable range
(1–6 Gy)
Anti-proliferative effects, G1 growth arrest and overall
radiosensitisation observed in all treated cell lines and
xenografts
NVP-BEZ 235 or LY294002 + rapamycin demonstrated
comparable radiosensitising effects
Kim et al.
(2) [83] 2008 NSCLC
In vitro (cell line): H460
In vivo (xenograft): H460 +
mice
Everolimus
Z-DEVD
mTOR inhibitor
Caspase -3
inhibitor
Variable (0–6Gy)
The combination of Z-DEVD and RAD001 more
potently radiosensitised H460 cells than individual
treatment alone.
Increased radiosensitisation predominantly through
enhanced autophagy
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1.2.2. Non-Small Cell Lung Cancer
NSCLC which accounts for over 85% of lung cancer is the leading cause of cancer related death
worldwide and may comprise of SCC, adenocarcinoma or other rarer histological subtypes [84].
Radiotherapy is used in the treatment of NSCLC with curative intent, palliative intent or as adjuvant
treatment. Outcomes following radiotherapy for NSCLC remains poor even in stage I disease [85].
Numerous studies have explored the role of PI3K/AKT/mTOR pathway inhibitors in radiosensitising
NSCLC (Table 2).
Kim et al. (1) and Konstantinidou et al. tested dual inhibitor NVP-BEZ235 in vitro using NSCLC
cell lines, and in vivo using xenograft mice [36,80]. Kim et al. (1) reports a statistically significant
reduction in the in vitro NSCLC cell viability following treatment with the dual inhibitor (p = 0.01) [80].
The two studies demonstrated radiosensitising effects through increased autophagy, cell proliferation
and cell cycle arrest at G1 phase. There was a significant delay in tumour growth observed in the
treated xenografts. Additionally, Konstantinidou et al. tried LY294002 with rapamycin, as a dual
pathway inhibition treatment [36]. LY294002 is a potent PI3K inhibitor which also weakly inhibits
other PI3K-like kinases such as mTOR, ATM and DNA-PK [86]. Using this combination, the authors
observed radiosensitising effects which were comparable to NVP-BEZ235 treatment. Toulany et al.
also used PI3K, mTOR and DNA-PKcs inhibitor PI-103, and MEK inhibitor PD98059 on an in vitro
cell line and in vivo xenograft experiment [38]. The authors demonstrated radiosensitising effects
through inhibited DNA DSB repair through suppressed DNA-PKcs activity [38]. In this study, short
term PI-103 only treatment led to radiotherapy sensitivity, but long-term treatment for 24 h led to
MEK/ERK dependent activation of the PI3K/AKT/mTOR pathway, resulting in radioresistance.
Kim et al. (2), Kim et al. (3), Mauceri et al. and Holler et al. used mTOR inhibitors (rapamycin
or everolimus) on NSCLC cell lines in vitro [39,81–83]. Only Mauceri et al. demonstrated isolated
mTOR inhibition could lead to radiosensitisation in NSCLC cell lines and xenografts [82]. Holler
et al., Kim et al. (2) and Kim et al. (3) found that isolated mTOR inhibition did not radiosensitise
NSCLC [39,81,83]. However, Holler et al. demonstrated that when a mTOR inhibitor is combined
with an AKT inhibitor (MK2206), significant radiosensitising effects may be observed in NSCLC cell
lines [39]. Deutsch et al. showed feasibility of everolimus with radiotherapy in NSCLC patients
in an early Phase I clinical trial [87]. Two further clinical trials are currently in progress evaluating
everolimus (ClinicalTrials.gov identifier, NCT00374140) and BKM120 (ClinicalTrials.gov identifier,
NCT02128724) as radiosensitisers in NSCLC patients.
1.3. Sensitising Glioblastoma Multiforme to Radiotherapy
GBM is the most common malignant central nervous system tumour in adults and is routinely
treated with chemoradiotherapy with or without surgery [88]. Survival remains poor with studies
reporting a median survival of just 14.6 months following chemoradiotherapy [89]. The majority of
research exploring the radiosensitising properties of PI3K/AKT/mTOR pathway inhibitors comes from
research using GBM cell lines and from a few early clinical trials in GBM patients (Tables 3 and 5).
Djuzenova et al., Del Alcazar et al., Kuger et al. (2), Wang et al., Mukherjee et al. and Cerniglia
et al., all demonstrated that dual PI3K/mTOR inhibitors successfully radiosensitise GBM cell lines
in vitro [49,74,90–93]. Del Alcazar et al. and Mukherjee et al. also conducted in vivo research using
xenograft mice [90,93]. The most frequently used dual PI3K/mTOR inhibitor was NVP-BEZ235. The
drug consistently demonstrated enhanced radiosensitisation of GBM cell lines and in two in vivo
mouse xenograft models (Table 3). Two studies using PI3K/mTOR/DNA-PK inhibitor PI-103 also
demonstrated enhanced radiosensitisation of GBM cell lines in vitro [49,94]. Dual inhibitors were
found to lead to autophagy, apoptosis, G2/M cell cycle arrest and impaired DNA DSB repair. Li et al.,
Kao et al. and Nakamura et al. tested LY294002 (PI3K and PI3K-like kinase inhibitor) in GBM cell
lines [95–97]. These studies showed enhanced radiosensitisation of GBM cell lines following treatment
with LY294002.
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Table 3. Preclinical studies exploring the role of PI3K, AKT and/or mTOR inhibitors radiosensitising GBM.
Author Year Type ofCancer Experimental Model Drug (s) Tested Drug Category
Radiotherapy
Dose Summary Outcome
Shi et al. [98] 2018 GBM
In vitro (cell lines): A172,
SHG44, and T98G
In vivo (xenograft)
NVP-BEZ235 PI3K and mTORinhibitor 2 Gy
Higher p27 and lower Bcl-2 expression in cells
treated with radiotherapy, temozolomide and
NVP-BEZ235
Inhibited tumour growth and prolonged survival
with combined treatment all three modalities
Djuzenova et
al. [49] 2016 GBM
In vitro (cell lines): GaMG,
SNB19 PI-103
PI3K, mTOR and
DNA-PK inhibitor 0, 2 Gy or 8 Gy
Enhanced radiosensitising effect following treatment
Enhanced radiosensitisation to heat shock protein 90
inhibitor NVP-AUY922
Choi et al. [94] 2014 GBM In vitro (cell lines): U251, U87,T98G
PI-103
Rapamycin
PI3K, mTOR and
DNA-PK inhibitor
mTOR inhibitor
Variable range
(0–8 Gy)
Radiotherapy with drug increased cytotoxic effects
No discernible radiosensitising effect with
rapamycin
Del Alcazar et
al. [90] 2014 GBM
In vitro (cell line): U87MG
In vivo (xenograft): GBM9 +
mice
NVP-BEZ235 PI3K and mTORinhibitor 0, 2 Gy or 10 Gy
Reduced expression of DNA-PKcs and ATM kinase
Attenuated repair of radiotherapy induced DNA
damage
Sensitized tumours to temozolomide and
radiotherapy
Kuger et al.
[2,91] 2013 GBM
In vitro (cell lines): GaMG
(PTEN wt, p53 mut), DK-MG
(PTEN wt, p53 wt), U373 (PTEN
mut, p53 mut), U87-MG (PTEN
mut, p53 wt)
NVP-BEZ235
Schedule 1: 24hr
before radiotherapy
Schedule 2: 1 h
before and for 48hr
post radiotherapy
PI3K and mTOR
inhibitor
Variable range
(0–8 Gy)
Enhanced radiosensitivity under schedule 2 as
opposed to schedule one
Protracted DNA repair
Prolonged G2/M arrest and apoptosis
Wang et al.
[92] 2013 GBM
In vitro (cell line): SU-2 cells
(Glioma stem cells) NVP-BEZ235
PI3K and mTOR
inhibitor
Variable range
(0–8 Gy)
Autophagy, increased apoptosis
Decreased DNA repair capacity
G1 cell cycle arrest
Cerniglia et al.
[74] 2012 GBM In vitro (cell line): U251MG NVP-BEZ235
PI3K and mTOR
inhibitor
Variable range
(0–6 Gy) Radiosensitises cells and induces autophagy
Mukherjee et
al. [93] 2012 GBM
In vitro (cell lines): U251, U118,
LN18, T98G, LN229, SF188,
1BR3, AT5, M059K, M059
In vivo (xenograft): U87 + mice
NVP-BEZ235 PI3K and mTORinhibitor 0, 2 Gy or 10 Gy
Reduced expression of ATM and DNA-PKcs
G2/M Arrest
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Table 3. Cont.
Author Year Type ofCancer Experimental Model Drug (s) Tested Drug Category
Radiotherapy
Dose Summary Outcome
Li et al. [95] 2009 GBM In vitro (cell line): U87MG
SH-5
MK-2206
LY294002
AKT inhibitor
AKT inhibitor
PI3K and PI3K-like
kinase inhibitor
Variable range
(0–9 Gy)
Enhanced radiosensitivity noted with all three
agents
Kao et al. [96] 2007 GBM In vitro (cell line): U251MG LY294002 PI3K and PI3K-likekinase inhibitor
Variable range
(0–6 Gy) Enhanced radiosensitivity following treatment
Nakamura et
al. [97] 2005 GBM In vitro (cell line): U251 MG
LY294002
Rapamycin
PI3K and PI3K-like
kinase inhibitor
mTOR inhibitor
Variable range
(0–8 Gy)
Low doses of LY294002 sensitized U251 MG to
clinically relevant doses of radiation
No effect observed with rapamycin
Shinohara et al.
[99] 2005 GBM
In vitro (cell lines): GL261,
endothelial cell line
In vivo (xenograft): GL261 +
mice
Everolimus mTOR inhibitor Variable range(0–7 Gy)
Reduced tumour growth by enhanced
radiosensitisation of the tumour vascular
endothelium
Eshleman et al.
[100] 2002 GBM
In vitro (cell lines): U87,
SKMG-3
In vitro (spheroids): U87
In vivo (xenograft): U87 + mice
Rapamycin mTOR inhibitor Variable range(0–10 Gy)
Rapamycin had no effect on cell lines
However, the drug significantly enhanced the
response to radiotherapy on xenograft and
spheroids following treatment
Cancers 2020, 12, 1278 16 of 29
Choi et al., Nakamura et al. and Eshleman et al. tested mTOR inhibitor rapamycin
in vitro [94,97,100]. All three studies showed no significant radiosensitising effect of this drug
on GBM cell lines. However, Eshelman et al. demonstrated rapamycin enhances radiotherapy
sensitivity of U87 spheroids and U87 xenografts [100]. Shinohara et al. studied the effects of mTOR
inhibitor everolimus on glioma cells and endothelial cells using in vitro cell line and in vivo mouse
model experiments [99]. This study demonstrated the role of mTOR inhibition on impaired tumour
blood supply thus leading to inhibition of tumour growth.
A phase-I trial by Sarkaraia et al. demonstrated that everolimus can be safely administered to GBM
patients in conjunction with a chemoradiotherapy treatment regimen comprising of temozolomide
and radiotherapy [101]. The authors recommend an everolimus dose of 70 mg/week (10 mg/day) for
future studies. However, a phase-II trial by Ma et al. demonstrated that the addition of 70 mg/week
of everolimus to standard therapy led to a moderate increase in toxicity with no appreciable benefit
in overall survival (p = 0.28) or progression free survival (p = 0.15) [102]. Another phase-II trial by
Chinnaiyan et al. which included 171 patients with GBM found that the addition of everolimus
(10 mg/day) to standard therapy led to a significant reduction in overall survival (p = 0.008) [103].
Wen et al. conducted a Phase I clinical trial using dual PI3K/mTOR inhibitor XL 765 [104]. The study
demonstrated feasibility of the drug in combination with current standard treatment. There was
moderate inhibition of the pathway components noted on skin biopsies from patients. The MTD
reported by the authors was 90 mg/day.
1.4. Sensitising Other Tumour Cells and Endothelial Cells to Radiotherapy
The radiosensitising properties of PI3K/AKT/mTOR inhibitors have also been demonstrated in
soft tissue sarcoma, bladder transitional cell carcinoma, hepatocellular carcinoma, metastatic renal cell
carcinoma Burkitt’s lymphoma (Table 4), SCC of the cervix (Table 2) and pancreatic cancer (Table 1).
Fokas et al. (2) radiosensitised soft tissue sarcoma cell lines and xenograft mice using NVP-BEZ235 [76].
This dual PI3K/mTOR inhibitor led to significant changes within the tumour microenvironment by
prolonging the time taken for the normalisation of tumour vascularity. The authors also compared
the efficacy of isolated PI3K inhibition using BKM120 against dual inhibition with NVP-BEZ235. The
dual inhibitor was a more potent radiosensitiser and led to impaired remodelling of the tumour
vasculature [76]. In 2009, Murphy et al. also demonstrated that mTOR inhibitor rapamycin can
effectively radiosensitise sarcoma cells in vitro [105].
Prevo et al. demonstrated that PI-103 can successfully radiosensitise sarcoma cell lines and T24
bladder transitional cell carcinoma (TCC) cell lines through cell cycle G1-M phase arrest and inhibited
DNA DSB repair [23]. Fokas et al. (1) demonstrated that dual inhibitors (NVP-BEZ235 and NVP-BGT
226) can effectively radiosensitise T24 bladder TCC cell lines and xenograft mice [77]. Assad et al. also
demonstrated that mTOR inhibition can effectively radiosensitise cervical SCC cell lines in vitro, at
radiotherapy doses as low as 2 Gy [79]. Other types of cancer that may be radiosensitised by pathway
inhibition include renal cell carcinoma, hepatocellular carcinoma and Burkitt’s lymphoma [106–108].
Given that radiotherapy is less frequently used in the treatment of the aforementioned cancers, the
clinical significance of this research is somewhat limited.
Several studies have also evaluated the role of pathway inhibition in radiosensitising endothelial
cells [50,77,99,105]. Resistance to radiotherapy may be induced by tumour revascularisation and
inhibiting cellular hypoxia [14]. The pathway inhibitors which sensitise tumour as well as endothelial
cells to radiotherapy, suppress the revascularisation of the tumour resulting in an enhanced response
to radiotherapy.
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Table 4. Preclinical studies exploring the role of PI3K, AKT and/or mTOR inhibitors radiosensitising other types of cancer.
Author Year Type ofCancer Experimental Model Drug (s) Tested Drug Category
Radiotherapy
Dose Summary Outcome
Detti et al.
[106] 2016
Renal cell
carcinoma
(RCC)
Human patient case-report Everolimus mTOR inhibitor Total dose = 20 Gy RCC vertebral metastases treated successfully withradiotherapy and everolimus
Liu et al. [107] 2014 HepatocellularCarcinoma In vitro (cell lines): Huh7, BNL
BKM120
Rapamycin
PI3K inhibitor
mTOR inhibitor
Variable range
(0–10 Gy)
Both drugs promoted apoptosis and reduced DSB
break repair to a certain extent
Dual inhibition with BKM120 and rapamycin
significantly enhanced radiosensitivity of treated
cells
Qiao et al.
[108] 2013
Human
Burkitt’s
Lymphoma
In vitro (cell lines): Namalwa,
Ramos, Raji
LY294002
SH-5
PI3K and PI3K-like
kinase inhibitor
AKT inhibitor
5Gy Enhanced apoptosis following treatment with thepathway inhibitors followed by radiotherapy
Fokas et al. (1)
[77] 2012
Bladder (TCC) In vitro (cell line): T24 NVP-BEZ235 PI3K and mTORinhibitor Variable range Dual inhibitors enhance radiation-induced killing of
endothelial cellsEndothelial
cells
In vitro (cell line): HUVEC,
HDMVC NVP-BGT226
PI3K and mTOR
inhibitor (0–6 Gy)
Fokas et al. (2)
[76] 2011 Sarcoma
In vitro (cell line): HT-1080
HRE-Luc
In vivo (xenograft): HT-1080 +
mice
NVP-BEZ235
BKM120
PI3K and mTOR
inhibitor
PI3K inhibitor
6 Gy
Dual inhibitor modulated the tumour
microenvironment
Radiosensitised tumours by prolonging the time
taken for normalisation of tumour vasculature
Murphy et al.
[105] 2009
Sarcoma
Endothelial
cells
In vitro (cell lines): SK-LMS-1
leiomyosarcoma, HT-1080
fibrosarcoma, SW-872
liposarcoma cells,
In vitro (cell line): HDMEC
Rapamycin mTOR inhibitor Variable range(0–6 Gy) Rapamycin radiosensitised all cell lines in vitro
Prevo et al.
[23] 2008
Sarcoma
Bladder (TCC) In vitro (cell line): HT-1080 T24 PI-103
PI3K, mTOR and
DNA-PK Inhibitor Variable (0–6 Gy)
Persistent DNA damage after treatment
G2/M phase arrest
Manegold et al.
[50] 2008
Endothelial
cells In vitro (cell line): HUVEC Everolimus mTOR inhibitor 10 Gy or 20 Gy
Endothelial cells most sensitised to radiotherapy by
mTOR inhibition
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1.5. Overcoming Radiotherapy Resistance by Pathway Blockade
Research has identified several biological processes which contribute to the radiosensitisation of
cancer, following PI3K/AKT/mTOR pathway inhibition. Most studies demonstrated a reduction in cell
proliferation following effective pathway inhibition and irradiation (Tables 1–4). The majority also
reported impaired DNA DSB repair following treatment with pathway inhibitors, characterised by
the persistence of excess λ-H2AX foci [18,23,39,49,64,73–75]. Several studies demonstrated reduced
expression of DNA-PKcs, the protein catalytic subunit of DNA-PK [18,38,66,90,93]. DNA-PK plays an
important role in DNA DSB repair [93]. There was enhanced apoptosis and autophagy [56,80,81,83].
Cell cycle progression was inhibited with numerous studies demonstrating cell cycle arrest at G2-M
phase following treatment with pathway inhibitors and radiotherapy [56–58,66,73,77,78,91,93]. Several
others showed cell cycle arrest at G1 phase [23,36,37,65]. The pathway inhibitors successfully led to
cell cycle checkpoint activation by inhibiting the inhibitors of cell cycle checkpoint proteins such as
TP53. Pathway inhibition also led to significant changes within the tumour microenvironment. There
was impaired tumour revascularisation likely through the inhibition of HIF-α and VEGF [65,78]. There
was inhibited cell migration [48,73,75]. Pathway inhibitors demonstrated the ability to radiosensitise
cells growing in the most hypoxic regions of a tumour, which harbour extreme pro-survival and
anti-apoptotic mutations [57,64].
Single pathway inhibition can be ineffective given that the PI3K/AKT/mTOR pathway has
numerous triggers (Figure 1) and direct activators of its downstream components, circumventing
the effects of this class of inhibitor. Isolated inhibition of mTOR or PI3K likely leads to activation
of AKT (the main effector of the pathway) by phosphorylation via the EGFR/RAS/RAF/MEK/ERK
pathway [38,49]. AKT inhibition in isolation is also unlikely to be effective because downstream
components of the pathway (e.g., mTOR) may be activated via alternative biological pathways [39].
This indirect activation of the PI3K/AKT/mTOR pathway is a crucial mechanism of radiotherapy
resistance [38,39,109]. A minimum two-point inhibition of key pathway components is therefore
essential to ensure effective downstream inhibition. This may explain the higher efficacy of dual
inhibitors such as NVP-BEZ235. The latter was the most frequently used dual PI3K and mTOR inhibitor
identified within this type of research. The drug consistently demonstrated radiosensitising effects on
in vitro cell line and in vivo xenograft experiments; in PC, CRC, GBM, H&N SCC, NSCLC, breast and
gynaecological cancer. Other potential dual or pan pathway inhibitor combinations (e.g., AKT/mTOR
or PI3K/mTOR and DNA-PK inhibition) have also been tried [38,39]. However, the current scientific
evidence available is limited for making discernible conclusions regarding the radiosensitising potential
of these alternative pathway inhibitor combinations.
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Figure 2. Targets for inhibition by various inhibitors along the PI3K/AKT/mTOR pathway.
1.6. Limitations, Challenges and Potential for Clinical Translation
There is significant variation in the methodology used in this research. There were multiple
different cell lines being used even within a given tumour type. The majority of this research in
rectal cancer utilised cell lines or xenograft models derived from colon cancer [18,23,48–50]. However,
radiotherapy is only used in the treatment of rectal cancer and not in colon cancer. This remains a
significant limitation for rectal cancer research. The advent of novel in vitro experimental models
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such as three-dimensional primary cell cultures (organoids) using primary rectal tumour tissue, will
undoubtedly contribute to novel insights [110]. Variations in radiotherapy regimes used across the
different studies was also a significant limitation. Standardisation of radiotherapy regimes preferably at
a clinically relevant dose for that tumour type will ensure greater comparability across future research.
The duration of treatment with pathway inhibitors varied considerably across the different studies.
Even though most authors emphasised the need for pathway inhibitors to be commenced prior to
traditional chemoradiotherapy, continued during and preferably for a period thereafter; there remains
a lack of consensus on the exact duration of treatment. There was also significant variations in the
outcome measures used within this in vitro and in vivo research. These factors render comparability
across different studies extremely difficult.
The challenges of toxicity, the complexity of pathway inhibitor combinations used, as well as the
sheer volume of different inhibitors that are available might be hindering translational research in this
field (Table 5, Figure 2). The dilemma facing the clinical researcher reviewing the scientific evidence is
which inhibitor they must choose for an early clinical trial. For example, we identified at least four
different dual PI3K and mTOR inhibitors of this pathway that have been used across the different
tumour types. This is a significant limitation in research in this area. Therefore, scientific research
should focus on a select few pathway inhibitors and pursue them to clinical trials to ensure effective
clinical translation.
A limited number of pharmacological inhibitors of this pathway have undergone early clinical
trials in combination with radiotherapy (Table 5). Several of these early clinical trials used mTOR
inhibitors. Frequent side effects of the most commonly used mTOR inhibitor everolimus included
mucositis, cutaneous rash and diarrhoea [61,62]. mTOR inhibitors were found to be safe in combination
with chemotherapy and/or radiotherapy in cervical cancer, PC and rectal cancer. However, a Phase-II
clinical trial from 2018 in GBM patients found overall survival in the treatment group with everolimus
to be significantly poorer compared to the standard treatment arm [103]. Most clinical trials using
mTOR inhibitors and radiotherapy evaluating pCR rates as an outcome have not shown a clinically
significant benefit [51,52]. However, this result should be interpreted with caution given the smaller
sample sizes observed in these early clinical trials. Therefore, more phase-II/III multi-arm randomised
control trials are needed to make clinically relevant conclusions to this regard.
Only one clinical trial involved a dual PI3K and mTOR inhibitor (Xl-765). The common
adverse effects observed with this drug when combined with radiotherapy included nausea, fatigue,
thrombocytopenia and diarrhoea [104]. NVP-BEZ235 was the most commonly used dual inhibitor
identified in this review. The drug has already been safely used in cancer patients in early clinical
trials, as the sole treatment or in combination with other chemotherapy [111]. However, it has yet to
undergo an early clinical trial in combination with radiotherapy. The growing evidence from scientific
research on the efficacy of dual PI3K and mTOR inhibitors as a radiosensitiser should be the primary
focus of current and future scientific research in this area. Clinical trials involving these dual pathway
inhibitors and radiotherapy remain scarce. There remains a need for early phase I/II clinical trials
using dual PI3K/inhibitors (e.g., NVP-BEZ235) in conjunction with radiotherapy (with or without
chemotherapy) in rectal cancer, PC, breast cancer, GBM, H&N SCC and NSCL.
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Table 5. Clinical trials exploring the role of PI3K, AKT and/or mTOR inhibitors radiosensitising various cancer.
Author Year Type ofCancer
No. of
Patients
Stage of
Disease
Experimental
Model Drug (s) Tested Drug Category Radiotherapy Dose Summary Outcome
de Melo et al.
[112] 2016
Cervical
Cancer 13
Primary stage
IIB, IIIA or
IIIB
Phase-I
clinical trial
Everolimus + cisplatin
+ radiotherapy
mTOR inhibitor with
traditional
chemoradiotherapy
External Beam 4500
cGy, 25
fractionsBrachytherapy:
2400 cGy, 4 insertions
Maximum tolerated dose (MTD) of
everolimus with radiotherapy and
cisplatin is 5 mg/day
Chinnaiyan et
al. [103] 2018 GBM 171
Newly
diagnosed
Phase-II
clinical trial
Everolimus (10mg/day)
+ temozolomide (TMZ)
+ radiotherapy
mTOR inhibitor with
traditional
chemoradiotherapy
60 Gy in 30 fractions
of 2 Gy each
Increased toxicity. Overall survival of
everolimus group worse (p = 0.008)
Ma et al. [102] 2015 GBM 100 Newlydiagnosed
Phase-II
clinical trial
Everolimus (70mg/wk)
+ temozolomide +
radiotherapy
mTOR inhibitor Total dose:60 Gy
Moderate toxicity observed following
everolimus radiotherapy and TMZ
No appreciable survival benefit over
control
Wen et al.
[104] 2015 GBM 54
Newly
diagnosed
Phase-I
clinical trial
XL 765 (30–90 mg once
daily or 20–50 mg twice
daily) + temozolomide
+ radiotherapy
PI3K and mTOR
inhibitor
Total dose of 60 Gy
(1.8–2 Gy a day, 5
days a week)
Drug + temozolomide with or without
radiotherapy feasible with favourable
safety profile
Moderate level of PI3K/mTOR pathway
inhibition observed on skin biopsies
MTD = 90 mg/day
Sarkaria et al.
[101] 2011 GBM 18
Newly
diagnosed
Phase-I
clinical trial
Everolimus (30 mg/wk
or 50 mg/wk or 70
mg/wk) +
temozolomide +
radiotherapy
mTOR inhibitor Total dose:60 Gy in 30 fractions
Favourable safety profile following
TMZ + radiotherapy
Changes in tumour metabolism
following everolimus
MTD = 70 mg/wk (10 mg/day)
NCT00858663 - Head andNeck SCC Not known Not known Phase-I Everolimus mTOR inhibitor Not known N/A
NCT02113878 - Head andNeck SCC Not known Not known Phase-Ib BKM120 PI3K inhibitor Not known N/A
Deutsch et al.
[87] 2015 NSCLC 26
Primary
NSCLC (Stage
III-IV)
Phase-I
clinical trial Everolimus mTOR inhibitor
Median total dose of
66 Gy (range, 28–66),
Median number of 33
fractions (range,
14–33)
Treatment feasible and safe
Authors recommend close observation
for pulmonary toxicity
NCT00374140
(In progress) - NSCLC Not known Not known Everolimus mTOR inhibitor Not known N/A
NCT02128724
(In progress) - NSCLC Not known Not known BKM120 PI3K inhibitor Not known N/A
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Table 5. Cont.
Author Year Type ofCancer
No. of
Patients
Stage of
Disease
Experimental
Model Drug (s) Tested Drug Category Radiotherapy Dose Summary Outcome
Azria et al.
[61] 2017
Prostate
Cancer
(high risk
locally
advanced)
14
Primary
locally
advanced non
metastatic
prostate
cancer (≥T3,
Gleason score
≥ 8)
Phase-I
clinical trial
Everolimus
(5 or 7.5 or 10
mg)+hormone therapy
+ Radiotherapy
mTOR inhibitor 74 Gy in 37 fractionsof 2 Gy
Everolimus was tolerated with hormone
and radiotherapy with minimal side
effects
MTD = 7.5 mg/day. Recommended dose
for phase-II studies is 5mg/day
Narayan et al.
[62] 2017
Prostate
Cancer
(recurrent)
18
Biochemical
recurrence
following
prostatectomy
Phase-I
clinical trial
Everolimus (5 or 7.5 or
10 mg) + radiotherapy mTOR inhibitor
66.6 Gy in 37 fractions
of 1.8 Gy
Everolimus dose of ≤10mg/day is safe
and toleration in combination with
radiotherapy
Gelsomino F
[52] 2017
Rectal
Cancer 12
Primary
resectable
rectal cancer
(T3-4, N0-2)
Phase-I/II
clinical trial (n
= 12)
Everolimus (2.5 or 5 or
7.5 or 10 mg) + 5FU +
radiotherapy
mTOR inhibitor with
traditional
chemoradiotherapy
1.8 Gy/fraction 50.4
Gy in 28 daily
fractions, 5
days/week
No increase in toxicity at any of the
doses with 5-FU and radiotherapy
No significant increase in pCR
MTD—10 mg
Buijsen et al.
[51] 2015
Rectal
Cancer 13
Primary
resectable
rectal cancer
(T2-3, N0-1)
Phase-I/II
clinical trial
Phase-I (n =
13)
Phase-II (n =
31)
Rapamycin (2 mg or 4
mg or 6 mg) +
radiotherapy
mTOR inhibitor 5 × 5 Gy
Neoadjuvant radiotherapy and
rapamycin feasible with no significant
increase in toxicity (MTD = 6mg)
No increase in post-operative
complications rates after delaying
duration to surgery to 6 weeks
Significant reduction in tumour
metabolic activity but pCR rate was still
10% within small sample sized study
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2. Conclusions
The PI3K/AKT/mTOR pathway has been identified as a potential radiotherapy resistance inducing
pathway in cancer. There is abundant evidence in the current scientific literature which supports the
notion that pharmacological inhibition of the PI3K/AKT/mTOR pathway components can radiosensitise
cancer. Changing the tumour microenvironment, disrupting DNA DSB repair, inhibiting cell growth,
cell proliferation and promoting cell death are a few of the mechanisms by which radiosensitisation
may occur. Many pharmacological inhibitors of this pathway have undergone safety and feasibility
studies in humans. However, there is limited clinical research available to make reliable conclusions
regarding the potency and safety of these inhibitors in radiosensitising tumours in patients.
Research has shown that isolated mTOR or PI3K inhibition can radiosensitise tumours in vitro
and in vivo. However, these drugs failed to demonstrate significant clinical efficacy during preliminary
trials. Consequently, the attention of researchers has shifted towards the radiosensitising properties
of dual PI3K and mTOR inhibitors. Recent scientific research has consistently demonstrated that
dual pathway component inhibition to be far superior at radiosensitising different tumour cell types.
Therefore, future laboratory as well as clinical research in this area should focus on the translational
potential of dual PI3K and mTOR inhibitors as radiosensitisers in cancer patients.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/5/1278/s1,
Figure S1: The PI3K/AKT/mTOR pathway activation leads to cell growth, increased protein synthesis, inhibited
apoptosis, cell cycle progression and proliferation.
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